Certara to Report Second Quarter 2025 Financial Results on August 6th, 2025
Certara (NASDAQ: CERT), a global leader in model-informed drug development, has scheduled its Q2 2025 earnings release for August 6th, 2025, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Certara (NASDAQ: CERT), a global leader in model-informed drug development, has scheduled its Q2 2025 earnings release for August 6th, 2025, after market close. The company will host a conference call at 5:00 PM ET to discuss the financial results.
Investors must pre-register online to participate in the conference call, with registration recommended at least one day in advance. Both a live and archived webcast will be accessible through Certara's investor relations website at ir.certara.com.
Details
News Market Reaction – CERT
The recorded move for CERT in the trading session of this news was +0.26%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RADNOR, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2025 after the market close on Wednesday, August 6th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET.
Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance.
A live and archived webcast of the event will be available on the “Investors” section of the Certara website at https://ir.certara.com/.
About Certara
Certara accelerates medicines using biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Learn more at certara.com.
Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com
Media Contact:
Alyssa Horowitz
certara@pancomm.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.